# Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

> **NCT07397819** · PHASE1,PHASE2 · RECRUITING · sponsor: **Dong sheng Zhang** · enrollment: 48 (estimated)

## Conditions studied

- Malignant Ascites

## Interventions

- **DRUG:** liposomal irinotecan monotherapy
- **DRUG:** liposomal irinotecan monotherapy
- **DRUG:** Liposomal Irinotecan + rmhTNF-NC
- **DRUG:** Liposomal Irinotecan + Bevacizumab

## Key facts

- **NCT ID:** NCT07397819
- **Lead sponsor:** Dong sheng Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-02-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07397819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07397819, "Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07397819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*